

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

RECEIVED
CENTRAL FAX CENTER
DEC 15 2006

REMARKS

I. Claim amendments

Claims 31, 33-44, 47, and 51-72 are pending. Claims 51-58 and 59-66 are withdrawn. Claim 32 has been canceled herein. Claim 31 has been amended to include, *inter alia*, a sterile pharmaceutically acceptable carrier or excipient. Claims 43, 45, 48, 51, 54, 55 and 57 have been amended to update claim dependencies. New claims 69-72 have been added and correspond to original claims 35, 45, 46 and 48, respectively.

II. Allowable Subject Matter

Applicants thank the examiner for granting an interview with the applicants' attorney, Li-Hsien Rin-Laures, and the applicants' agent, Jeanne Brashear, on November 15, 2006. Applicants are appreciative for the examiner's acknowledgement during the interview that claims 69-72, as presented in the after-final amendment, are considered free of prior art and allowable. Due the examiner's comments regarding the allowability of claims 69-72, it appears that claims 43, 51, 54, 55, 57 and 59-66, which depend from claims 69-72, also contain allowable subject matter.

III. The Rejection Under 35 U.S.C. § 102(b) May Properly Be Withdrawn.

The examiner rejected claims 31-34, 42, 43 and 67-68 under 35 U.S.C. § 102(b) as allegedly being anticipated by Saito et al., Proc. Natl. Acad. USA, 92:10227-10231, 1995 (hereinafter "Saito"). As indicated in the response to the previous Office action, Saito discloses a composition comprising a vector-mediated drug delivery system composed of a conjugate of A β ¹⁻⁴⁰, streptavidin, biotin and the OX26 monoclonal antibody to the transferrin receptor, wherein the OX26 monoclonal antibody is intended to deliver the composition across the blood brain barrier (BBB). See page 10227, 2nd column, lines 2-5 and Figure 1.

During the interview, applicants discussed the differences between Saito and the present invention. Saito uses OX26 monoclonal antibody (an antibody that binds to the rat transferrin receptor) to deliver amyloid- β ¹⁻⁴⁰ to the brain for diagnostic purposes. In contrast, the applicants use amyloid-beta (A β) polypeptide to deliver a non-A β polypeptide to the central nervous system (CNS). Applicants note that, solely to expedite prosecution, claim 31 has been amended to recite therapeutic compositions that include "a sterile pharmaceutically acceptable carrier or excipient" and that are used for treating a patient diagnosed with a CNS disorder. Support for this amendment can be found, for example, at page 12, lines 5-25.

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

Saito explicitly teaches that its delivery system is used for neuroimaging A β amyloid plaques. Saito provides no disclosure for using the composition disclosed to treat any subject, much less a human that has been diagnosed with a CNS disorder. Thus, Saito does not disclose a *therapeutic* composition comprising a sterile pharmaceutically acceptable carrier or excipient. The Examiner has not shown how the diagnostic composition disclosed in Saito falls within claims directed to a therapeutic composition for treating a CNS disorder, as recited in claim 31. Anticipation requires that the cited art disclose each and every element of the claims, which is not the case here.

In view of the foregoing, applicants respectfully request that the rejection of claims 31-34, 42 and 43 under 35 U.S.C. §102(b) be withdrawn.

With respect to claims 67-68, Saito cannot provide the basis for an anticipation rejection for claims 67-68 because Saito does not teach that the A β polypeptide is *covalently linked* to a non-A β polypeptide. Rather, the A β 1-40 is non-covalently bound to the OX26 monoclonal antibody through a non-covalent association between streptavidin and biotin. See the illustration in Figure 1 of Saito, which shows that the A β 1-40 is covalently linked to the biotin, which non-covalently associates with the avidin analog, which in turn is covalently linked to the OX26 antibody.

It is well known in the art that the interaction between streptavidin and biotin is a *non-covalent* linkage. See, for example, the abstract of Weber et al., Science, 243:85-88 (1989), set forth as Appendix A. Accordingly, because Saito does not disclose an A β polypeptide that is *covalently linked* to a non-A β polypeptide, Saito does not disclose each and every element of claim 67 and therefore cannot destroy the novelty of claim 67 and those claims dependent thereon. In view of the foregoing, applicants respectfully request that the rejection of claims 67-68 under 35 U.S.C. §102(b) be withdrawn.

IV. The Rejection of Claim 44 Under 35 U.S.C. § 103(a) May Properly Be Withdrawn.

The examiner rejected claim 44 under 35 U.S.C. § 103(a) as allegedly being unpatentable over Saito. The examiner asserts that "it would have been *prima facie* obvious to a person of ordinary skill in the art to use A β 1-42 polypeptide to construct the molecule as disclosed by Saito."

Claim 44 depends indirectly from claim 31. As discussed in the previous section, Saito does not teach or suggest a therapeutic composition for administration to a human patient that has been diagnosed with a CNS disorder, but rather suggests the use of OX26 monoclonal antibody to

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

deliver A β polypeptide for neuroimaging the A β amyloid plaques. Moreover, Saito does not state that the composition described therein included a sterile pharmaceutically-acceptable carrier or excipient.

Even if, assuming for the purposes of argument, the delivery system of Saito were to be used to deliver a therapeutic agent, then Saito's teaching would lead one of ordinary skill in the art to link OX26 monoclonal antibody (which is the delivery agent) to a *different* non-A β agent (a therapeutic agent, rather than a diagnostic agent), and therefore completely remove A β from the delivery system. Saito therefore teaches away from the present invention.

Accordingly, Saito fails to teach or suggest all of the limitations of the claims and motivates construction of an entirely different composition for therapeutic purposes (i.e., one which lacks an A β polypeptide). Therefore, in view of Saito's failure to teach or suggest the claimed invention, applicants respectfully submit that the claims are novel and inventive over Saito, and reconsideration and withdrawal of the rejection is respectfully requested.

V. The Rejection of Claims 36-40 and 49-50 Under 35 U.S.C. § 103(a) May Properly Be Withdrawn.

The examiner rejected claims 36-40 and 49-50 under 35 U.S.C. § 103(a) as allegedly being unpatentable over Saito in view of Solomon et al., (WO 99/60024). The examiner asserts that "it would have been obvious to a person of ordinary skill in the art to modify chimeric polypeptide of Saito to include fragments or chimeric antibodies in the construct, or to label the antibody." Applicants respectfully disagree with the examiner's assertion and request reconsideration in view of the following remarks.

One of ordinary skill in the art would not have been motivated to substitute the anti-amyloid antibodies disclosed by Solomon for the OX26 monoclonal antibody in the conjugate disclosed in Saito because the OX26 antibody is required as the delivery agent. To the extent that the examiner cites Solomon for its disclosure of "fragments or chimeric antibodies . . . or to label the antibody," such a modification of the OX26 monoclonal antibody of Saito does not teach or suggest the invention recited in claims 36-40, which is a therapeutic composition comprising an A β polypeptide linked to a non-A β polypeptide for treating a human patient that has been diagnosed with a CNS disorder. Accordingly, no combination of Saito and Solomon teaches or suggests all of the limitations of the claims and the rejection may properly be withdrawn.

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

VI. The Rejection of Claim 41 Under 35 U.S.C. § 103(a) May Properly Be Withdrawn.

The examiner rejected claim 41 under 35 U.S.C. § 103(a) as allegedly being unpatentable over Saito in view of Poduslo (U.S. Patent No. 5,670,477). The examiner asserts that "it would have been obvious to a person of ordinary skill in the art to conjugate a molecule intended for delivery through blood-brain-barrier to a polyamine as disclosed in '477 patent. One of ordinary skill in the art would have been motivated to do so because '477 patent specifically teaches the advantages of linking polyamine to a compound to be delivered to the brain." Applicants respectfully disagree with the examiner's assertion and request reconsideration in view of the following remarks.

Saito and Poduslo are improperly combined because the examiner has not shown where there is a teaching in either reference or any motivation to combine references that each teach a different method for enhancing delivery across the blood brain barrier, nor has the examiner shown a reasonable expectation that combining polyamine modification with OX26 monoclonal antibody-based delivery would meet with success. One of ordinary skill would have thought it possible that polyamine modification of the OX26 monoclonal antibody could reduce its ability to transport across the blood brain barrier.

Moreover, as discussed above in Sections III and IV, Saito does not teach or suggest the claimed composition and therefore cannot provide the basis for an obviousness rejection for any of the pending claims. Poduslo, which teaches modification of a compound by conjugating it to a polyamine, fails to provide the disclosure lacking from Saito. Accordingly, no combination of Saito and Poduslo teaches or suggests all of the limitations of the claims (e.g., composition for treating a human patient that has been diagnosed with a CNS disorder) and there is no teaching or suggestion in either Saito or Solomon that a composition comprising an A β polypeptide linked to a non-A β polypeptide can be used to treat a human patient that have been diagnosed with a CNS disorder. Therefore, no combination of these references teaches or suggests the compositions as recited in the claims. Accordingly, applicants respectfully submit that claim 41 is novel and inventive over Saito in view of Poduslo and the rejection may properly be withdrawn.

VII. Conclusion

It is believed that the foregoing responds to all of the examiner's concerns. If the examiner believes that a telephone conversation would expedite allowance of the claims, she is

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

invited to contact the undersigned agent or Li-Hsien Rin-Laures, attorney for applicants, at the number below. The Director is hereby authorized to charge any additional fees associated with the filing of this paper to Deposit Account No. 13-2855, under order no. 01017/30016A.

Dated: December 15, 2006

Respectfully submitted,

By Jeanne M. Brashear
Jeanne M. Brashear
Registration No.: 56,301
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Agent for Applicant

Application No. 10/796,522
Amendment dated December 15, 2006
Reply to Office Action of August 15, 2006

Docket No.: 01017/30016A

APPENDIX A

- Egg albumin (Sigma) and *Peritris* (Connaught Laboratories) were administered according to protocol described in M. H. Perdue, M. Chung, D. G. Gall, *Gastroenterology* 86, 391 (1984).
11. S. J. King *et al.*, *Eur. J. Immunol.* 16, 151 (1986); S. J. King and H. R. P. Miller *Immunology* 51, 653 (1984).
 12. K. J. Bloch *et al.*, *Gastroenterology* 77, 1039 (1979); E. Jarrett and H. Bazin, *Nature* 251, 613 (1974); *Clin. Exp. Immunol.* 30, 330 (1977).
 13. Animals were removed from the colony room and placed in plastic cages inside concrete-encased (soundproof) cabinets. A light flashed at an alteration rate of 300 ms, and background noise was provided by ventilation fans. The AV CS was based on that used by G. MacQueen and S. Siegel (*Behav. Neurosci.*, in press).
 14. An enzyme-linked immunosorbent assay (ELISA) for detecting RMCP II was modified from Miller *et al.* (7). Rats were anesthetized with ether, and blood was obtained from the retro-orbital plexus. Sera were collected and stored at -20°C . The wells of a tissue culture microtiter plate (Nunc/Delta) were coated with 0.5 mg of RMCP II per milliliter of a 0.2M carbonate buffer, pH 9.6. Samples and standards were diluted in PBS containing 0.3% w/v bovine serum albumin, 0.02% v/v polyoxyethylene-sorbitan monolaurate (Tween 20), and 0.02% w/v sodium azide and incubated for 16 to 24 hours with a diluted specific rabbit antiserum to RMCP II (anti-RMCP II) from which all activity against RMCP I had been removed by immunoadsorption. After extensive washing of the plates, 100 μl of samples and standards were placed in duplicate wells and incubated for 16 to 24 hours. Plates were again washed several times and rabbit antibody bound to the plate was detected with an alkaline phosphatase conjugated goat to rabbit antibody (ICN) and a sodium-p-nitrophenyl phosphate substrate (Sigma). Results were calculated on the basis of a standard curve constructed with the use of known concentrations of purified RMCP II. Antibodies to RMCP II were raised in rabbits with purified RMCP II. Antisera were absorbed twice with RMCP I covalently attached to Sepharose 4B. The final preparation showed strong binding to RMCP II on immunoblot analysis, with a weak cross-reaction to RMCP I, and no detectable binding to cathepsin G. The specificity of this assay was confirmed with homogenates of tongue tissue known to contain high levels of RMCP I, but no RMCP II. Although there was some binding to RMCP I on the immunoblot, no binding was detected in the liquid phase.
 15. Morphological studies have shown the presence of mast cells in peripheral nerves (Y. Olsson, *Acta Neurol. Scand.* 47, 357 (1971)) and autonomic ganglia (G. Gabel, *Structure of the Autonomic Nervous System* (Chapman and Hall, London, 1976)), a consistent ultrastructural relationship between mucosal mast cells and nerves in normal and nematode-infected rat lamina propria was detected (R. H. Stead, *Proc. Natl. Acad. Sci. U.S.A.* 84, 2975 (1987)).
 16. Substance P causes release of histamine from mast cells in vitro (F. Shamahan *et al.*, *J. Immunol.* 135, 1331 (1985); O. Hagemark, T. Hockfelt, B. Pernow, *J. Invest. Dermatol.* 71, 233 (1978)), and mast cells and substance P containing nerves may be involved in the vasodilatory response to noxious stimuli (J. C. Foreman and C. C. Jordan, *J. Physiol.* 238, 58 (1982)).
 17. Evidence has also supported a role for functional nerve-mast cell interactions. A. R. Leff *et al.* (*J. Physiol.* 136, 1066 (1986)) demonstrated that vagal stimulation causes enhanced histamine release from mast cells after antigen challenge, and a decrease in mast cell granularity has been shown after electrical field stimulation (T. Bani-Sacchi *et al.*, *J. Physiol.* 371, 29 (1986)). Studies of hypersensitivity reactions in the gut and lung indicate a neural component in the changes in epithelial ion transport induced by antigen (Y. Harari *et al.*, *J. Immunol.* 138, 1250 (1987); see M. H. Perdue in (10)).
 18. D. Refius, F. Pearce, J. Riesenstock, in *Food Allergy and Intolerance*, J. Brostoff and S. J. Challacombe, Eds. (Bailliere-Tindall, London, 1986), pp. 88-98,

- E. G. Seidman, D. G. Hanson, W. A. Walker, *Gastroenterology* 90, 120 (1986); J. B. Kirchner and R. G. Shorter, *N. Engl. J. Med.* 306, 837 (1982).
19. J. C. Foreman, *Allergy* 42, 1 (1987); D. M. Barnes, *Science* 232, 160 (1986); P. J. Barnes, *Lancet* i 242 (1986).
20. Supported by grants from the Medical Research

Council of Canada, the Natural Sciences and Engineering Research Council of Canada, and the Foundation for Ileitis and Colitis. We thank L. Neilson for technical assistance and R. Woodbury for the RCMP II and the anti-RCMP II.

18 July 1988, accepted 17 October 1988

Structural Origins of High-Affinity Biotin Binding to Streptavidin

PATRICIA C. WEBER, D. H. OHLENDORF, J. J. WENDOLSKI, F. R. SALEMME*

The high affinity of the noncovalent interaction between biotin and streptavidin forms the basis for many diagnostic assays that require the formation of an irreversible and specific linkage between biological macromolecules. Comparison of the refined crystal structures of apo and a streptavidin:biotin complex shows that the high affinity results from several factors. These factors include the formation of multiple hydrogen bonds and van der Waals interactions between biotin and the protein, together with the ordering of surface polypeptide loops that bury the biotin in the protein interior. Structural alterations at the biotin binding site produce quaternary changes in the streptavidin tetramer. These changes apparently propagate through cooperative deformations in the twisted β sheets that link tetramer subunits.

STREPTAVIDIN IS A TETRAMERIC PROTEIN (molecular weight = $4 \times 15,000$) isolated from the actinobacterium *Streptomyces avidinii* (1). Streptavidin, and the homologous protein avidin, are remarkable for their ability to bind up to four molecules of *d*-biotin with unusually high affinity [dissociation constant $K_d = 10^{-15}\text{M}$ (1, 2)]. Although these proteins may function as antibiotics that deplete the environment of the essential vitamin biotin, they have been studied primarily as paradigms for understanding high-affinity protein-ligand interactions (2). At the same time, the ability of streptavidin and avidin to bind derivatized forms of biotin has led to their widespread use in diagnostic assays that require formation of an essentially irreversible and specific linkage between biological macromolecules (3). We undertook the structure determination of streptavidin, with and without bound biotin, to uncover the origins of high affinity of the protein for biotin.

Streptavidin was obtained from several commercial sources and produced different crystal forms during the course of the study. The most consistent results were obtained with a fragment of the native 159-residue streptavidin chain, incorporating residues 13 through 133. Numerous studies indicate that this truncated form of the molecule

binds biotin with an affinity that is the same or similar to alternative longer versions of the protein. Moreover, in some cases it appeared that preparations identified as full-length material crystallized isomorphously with the truncated fragment, suggesting that the molecular termini may be relatively flexible or disordered. Crystallization conditions for apostreptavidin and its biotin complex were found by robotic grid search methods (4). Both formed crystals from a polyethylene glycol-LiCl mixture, although the streptavidin:biotin complex crystallizes at pH 7.8 [space group $I4_122$, $a = b = 99.4$ Å, $c = 125.8$ Å (5)], whereas apostreptavidin crystallizes at pH 2.4 [space group $I4_122$, $a = b = 58.3$ Å, $c = 172.5$ Å]. Unit cell parameters of truncated apostreptavidin are similar to those reported by Pahler *et al.* (6), although the crystals studied here grow at lower pH, and diffract to higher resolution ($d_{\min} = 1.7$ Å).

The structure of apostreptavidin was determined by multiple isomorphous replacement techniques. X-ray diffraction data for parent crystals and several isomorphous replacement derivatives were collected using a multiwire area detector and processed with the Xengen data-reduction package (7). Successful derivatives included $\text{K}_2\text{Pt}(\text{SCN})_6$, which was prepared by soaking crystals in the heavy metal solution, and an iodine derivative prepared by crystallizing protein after reaction in solution (8). Substitution sites were located by an automated search procedure (9) performed on the heavy atom difference Patterson maps. Phases were ob-

Central Research & Development Department, E. I. du Pont de Nemours and Company, Inc., Du Pont Experimental Station, ES 228/320, Wilmington, DE 19880-0226.

*To whom correspondence should be addressed.

tained after refinement of heavy atom positions by the origin-removed different Patterson method (10) and used to compute a 2.6 Å resolution electron density map (11).

The electron density map was interpreted with the graphics program FRODO (12). Identification of several Trp and other large residues allowed an initial α -carbon backbone trace and sequence assignment to be made for ~70% of the structure, organized primarily as antiparallel β sheet. A partial atomic model was constructed from the α -carbon trace with the use of fragment superposition (13) from a database of refined protein structures (14). Complete backbone fragments that best fit the α -carbon trace were incorporated into the model. Side chains were positioned by displaying possible rotamers for each amino acid from a library (15) and by including coordinates for the rotamer that best fit the electron density. Phases computed from the partial model were combined with the multiple isomorphous replacement phases and used to generate an improved electron density map whose interpretation defined the remainder of the molecular structure. The structure was refined with the restrained least-squares method of Hendrickson and Konert (16) and manual rebuildings in electron density maps. Although the refinement proceeded smoothly, two surface loops lacked defined density and appeared disordered in the final structure. The crystallographic R -factor for apostreptavidin, including residues 13 to 46, 49 to 63, and 69 to 133, as well as 33 water molecules, is 0.21 for 11,120 reflections [$F_{\text{observed}} > \sigma(F_{\text{observed}})$] between 5.0 and 1.8 Å resolution.

The structure of the streptavidin:biotin complex was solved with the use of symmetry-constrained searches of the complex unit cell with the apostreptavidin tetramer (17). Apostreptavidin crystallizes with a monomer in the asymmetric unit, so that subunits of the tetramer are related by crystallographic dyad axes. Since tetramers in the nonisomorphous crystals of the streptavidin:biotin complex could also pack with subunits related by crystal symmetry, we searched that cell using the apostreptavidin tetramer as the probe molecule (18). A maximum correlation coefficient of 0.56 was obtained for 1363 intensities between 4 and 5 Å resolution when the streptavidin tetramer was positioned at the origin of the streptavidin:biotin complex unit cell with all three of its dyad axes coincident with the crystallographic dyad axes. This result shows that both apo and liganded forms of streptavidin are tetramers with subunits related by 222 point group symmetry. The initial crystallographic R -factor for apostreptavidin positioned in the biotin:streptavidin unit cell




Fig. 1. Streptavidin structure. (A) Cartoon sequentially showing the β sheet folding path of the hydrogen-bonded dimer, the apostreptavidin structure, and changes upon biotin binding. These changes include ordering of two loops (shown dashed) incorporating residues 45 to 50 and 63 to 69. (B) Stereoview of a streptavidin subunit with biotin bound, showing β barrel hydrogen bonds as thin lines. Residues 13 through 133 form an eight-stranded antiparallel β sheet wrapped as a slightly flattened barrel.

was 0.41 for data from 5.0 to 2.6 Å resolution.

The structure of the streptavidin:biotin complex was refined by a combination of conventional restrained least-squares methods and crystallographically constrained molecular dynamics. The molecular dynamics refinement protocol essentially followed previous work (19), but was implemented in our laboratory by combining features of AMBER (20), PROLSQ (16), and PROFIT (21). The crystallographic R -factor of the streptavidin:biotin complex, including all residues between sequence positions 13 and 133, biotin, and nine water molecules, is 0.22 for 7379 reflections with $F_{\text{observed}} > \sigma(F_{\text{observed}})$ between 5.0 and 2.6 Å resolution [coordinates will be deposited in the Brookhaven Protein Data Bank (14)].

Streptavidin subunits are organized as eight-stranded, sequentially connected, antiparallel β sheets. The sheets are formed of coiled polypeptide chains with a staggered pattern of adjacent strand hydrogen-bond registration (22). This arrangement pro-

duces a cyclically hydrogen-bonded barrel with several extended hairpin loops, including one near the carboxyl terminus whose edge is free to form a more extended β sheet (Fig. 1). Pairs of streptavidin barrels hydrogen bond together at this free edge to form symmetric dimers that resemble basketball nets connected by their rims at a 45° angle. The naturally occurring streptavidin tetramer is formed by interdigitating a pair of dimers, with their dyad axes coincident, to produce a particle with 222 point group symmetry. The tetramer is stabilized by extensive van der Waals interactions between the subunit barrel surfaces, which have complementary curvatures (Fig. 2).

Biotin binds in pockets at the ends of each of the streptavidin β barrels (Fig. 1). The residues lining the pockets are primarily aromatic or polar amino acids or both. These groups are solvent exposed in apostreptavidin so that several water molecules occupy the biotin binding site. Biotin binding involves displacement of bound water, formation of multiple interactions between biotin heteroatoms and the binding site

residues, and burial of the biotin through ordering of a surface loop (residues 45 to 50) that is disordered in apotreptavidin. Polar interactions made between biotin heteroat-

oms and the protein include (i) an extensive pattern of hydrogen bonds with the biotin ureido group, where no less than five protein residues form associations; (ii) a possi-

ble interaction between biotin sulfur and the hydroxyl group of Thr⁹⁰; and (iii) hydrogen-bonded interactions with the valeryl carboxyl group that includes a hydrogen bond from the backbone NH of Asn⁴⁹, which becomes ordered on biotin binding (Fig. 3). Several other residues lining the binding site are immobilized by hydrogen bonds, which are formed in many cases with the same residues that hydrogen bond to biotin. These include Trp residues 79, 92, and 108 that pack around the biotin tetrahydrothiophene ring, and which, together with Trp¹²⁰ from the cyad-related subunit, form a hydrophobic biotin binding site. As a result of this extensive pattern of interactions, resulting in part from the ordering of loop 45 to 50, bound biotin is essentially buried in the complex with only the valeryl carboxyl oxygens partially accessible to solvent.

Experimental studies of the binding of biotin analogs to avidin, a tetrameric protein from avian egg white that shares 38% sequence identity (23) with the crystallographically defined streptavidin, suggest that interactions made with the ureido ring system predominate in stabilizing the biotin-protein complex (2). An unusual aspect of the interaction involves participation of the bio-





Fig. 2. Stereoviews of the streptavidin tetramer. (**Top**) Tetramer with bound biotins (backbone atoms), viewed along dyad symmetry axis relating hydrogen-bonded subunits (hydrogen bonds in red). (**Bottom**) Hydrogen-bond circuit representation of the tetramer, as defined by sheet hydrogen bonds and backbone amide group atoms. This representation emphasizes the continuity of the interactions that distribute forces throughout the barrels and across the subunit dimer axes.



6 JANUARY 1989

REPORTS 87

BEST AVAILABLE COPY




Fig. 4. Streptavidin quaternary structural changes. Yellow lines show α -carbon backbone trace of apo-streptavidin and blue lines show streptavidin with biotin bound. Pairs of hydrogen-bonded dimers have been separated by 15 Å along the horizontal tetramer dyad axis for clarity. Changes in the hydrogen-bonded dimer geometry produce relative rotations of the dimers about the horizontal dyad. Tetramer subunits of both the apo-streptavidin and streptavidin:biotin complex crystals are related by crystal-symmetry operations. The root-mean-square (rms) displacement for 112 common subunit Ca atoms, relative to the origin defined by the intersection of the tetramer 222 symmetry axes is 2.0 Å; the rms fit for the 67 Ca atoms in the β barrel is 0.7 Å in this frame. Superpositioning individual subunits gives an rms of 1.9 Å for all 112 Ca atoms common to the apo and liganded proteins and 0.3 Å for the 67 β barrel Ca atoms.

tin ureido group in an extended hydrogen-bond network anchored by the buried carboxyl group of Asp¹²⁸ that hydrogen bonds one ureido NH. The latter hydrogen bond could stabilize resonance forms that localize positive charge on biotin nitrogens and negative charge at the biotin ureido oxygen. Indeed, the ureido oxygen forms three hydrogen bonds, arranged with tetrahedral geometry, suggesting that the groups involved stabilize an sp^3 oxyanion (Fig. 3B). Comparison of streptavidin and avian avidin show that all of the groups that directly bind biotin are conserved with the exception of Ser⁴³, which is replaced by Thr with similar functionality, and Asp¹²⁸, which, surprisingly, is substituted by Asn (23). These changes may reflect some differences in the way biotin is stabilized in streptavidin and avidin. However, the analog of the residue that hydrogen bonds to Asp¹²⁸ in streptavidin, Gln⁸⁴, is substituted by Asp in avidin, so that slightly different but similar polarization networks could be functional in both proteins. Although biotin makes additional hydrophobic and hydrogen-binding interactions that assist binding, the hydrogen-bonded interactions with the valeryl group appear to play a lesser role. This group is partially accessible in the complex and provides the covalent attachment sites for linking biotin with other biomolecules (5).

Apo and liganded streptavidin differ in quaternary structure. Although the observed changes could in part reflect differences in crystal pH or lattice interactions and there is currently no evidence for subunit cooperativity, the pattern of quaternary changes

nevertheless suggests a consistent mechanism of subunit communication. Subunit differences between apo and liganded streptavidin include the formation of extensive biotin:protein interactions, concomitant ordering of two surface loops, and formation of a salt link between Glu⁵¹ and Arg⁸⁴ from adjacent loops. Collectively, these interactions cause the subunit barrels to flatten slightly and become more tightly wrapped. Because the subunit barrels are part of a more extended β sheet that forms the hydrogen-bonded dimer (Figs. 1 and 2), and the barrel exteriors pack at the dimer-dimer interface (Figs. 2 and 4), changes in barrel curvature effect both hydrogen-bonded dimer geometry and dimer-dimer packing. The net result of the change in subunit barrel curvature is to alter the twist of β sheet that connects dimer subunits, which produces a slight increase in the angle between the barrel domains. The tetramer adjusts to the changes in dimer sheet twist and preserves the complementary sheet packing by a 5.4° rotation of the dimer subunits around the corresponding tetramer dyad axis (Fig. 4).

The unusually high affinity of streptavidin for biotin reflects participation of a number of factors, the analogs of which have been previously encountered individually in other protein-ligand interactions. These factors include oriented dipole arrays to stabilize bound oxyanions [for example, the oxyanion hole in serine proteases (24)], hydrogen-bond dipole networks to alter charge distribution on bound ligands [such as the serine protease charge relay system (24)], and dis-

order-order transitions to sequester bound ligands from the solvent environment [as in triose phosphate isomerase (25)]. In streptavidin, these factors, together with quaternary changes in structure, combine to produce both strong binding and a high activation energy for dissociation that characterize the near irreversibility of the biotin:streptavidin interaction.

REFERENCES AND NOTES

1. L. Chaiet and F. J. Wolf, *Arch. Biochem. Biophys.* **106**, 1 (1964).
2. N. M. Green, *Adv. Protein Chem.* **29**, 85 (1975).
3. P. R. Langer, A. A. Waldrop, D. C. Ward, *Proc. Natl. Acad. Sci. U.S.A.* **78**, 6633 (1981); J. J. Leary, D. J. Briggs, D. C. Ward, *ibid.* **80**, 4045 (1983).
4. M. J. Cox and P. C. Weber, *J. Appl. Cryst.* **20**, 366 (1987); *J. Cryst. Growth* **90**, 318 (1988).
5. P. C. Weber, M. J. Cox, P. R. Salemme, D. H. Ohlendorf, *J. Biol. Chem.* **262**, 12728 (1987).
6. A. Pabst et al., *ibid.*, p. 13933.
7. A. J. Howard et al., *J. Appl. Cryst.* **20**, 383 (1987).
8. J. Wolff and I. Corvelli, *Eur. J. Biochem.* **9**, 371 (1969).
9. T. C. Terwilliger et al., *Acta Cryst.* **A43**, 1 (1987).
10. T. C. Terwilliger and D. Eisenberg, *ibid.* **A39**, 813 (1983).
11. The agreement between multiple observed diffraction intensities, $R_m = \{[I_o - \langle I \rangle] / I_o\}$ (rms, root-mean-square), for 84,062 observations of 9,225 unique reflections to 2.6 Å resolution was 0.054 for the streptavidin:biotin complex, and the R_m for apo-streptavidin native crystals was 0.052 for 89,393 observations of 13,496 observations to 1.7 Å resolution. The fractional difference in diffraction amplitudes to 2.2 Å resolution between native and derivative crystals of apo-streptavidin was 0.14 for iodinated apo-streptavidin and 0.19 for the crystal soaked in $K_2Pt(SCN)_6$. In the apo-streptavidin structure determination by multiple isomorphous replacement techniques (10), the mean figure of merit for 4640 reflections to 2.6 Å resolution was 0.62, and the ratio of the mean heavy atom scattering factor to the mean lack of closure (f_o/E) was 1.4 for accurate reflections of the platinum derivative and 0.8 for those of the iodinated apo-streptavidin.
12. T. A. Jones, *J. Appl. Cryst.* **11**, 268 (1978).
13. — and S. Thirup, *EMBO J.* **5**, 819 (1986); B. C. Finzel, *Protein Struct. Funct. Genet.*, in press.
14. F. C. Bernstein et al., *J. Mol. Biol.* **112**, 535 (1977).
15. J. W. Ponder and F. M. Richards, *ibid.* **193**, 775 (1987).
16. W. A. Hendrickson and J. H. Konner, in *Molecular Structure, Function, Conformation and Evolution*, R. Srinivasan, Ed. (Pergamon, Oxford, 1980), vol. 1, pp. 43–57.
17. M. Fujinaga and R. Read, *J. Appl. Cryst.* **20**, 517 (1987).
18. The apo-streptavidin tetramer was positioned with a twofold symmetry axis coincident with a crystallographic dyad axis of the streptavidin:biotin unit cell. The correlation coefficient between observed and calculated structure factors was calculated for each orientation of the tetramer as it was rotated 180° in 3° steps about, and translated in 1 Å increments along, the crystal twofold axes.
19. A. T. Brünger, *J. Mol. Biol.* **203**, 803 (1988).
20. P. Weiner and P. A. Kollman, *J. Comput. Chem.* **2**, 287 (1981); S. J. Weiner et al., *J. Am. Chem. Soc.* **106**, 765 (1984).
21. B. C. Finzel, *J. Appl. Cryst.* **20**, 53 (1987).
22. F. R. Salemme, *Prog. Biophys. Mol. Biol.* **42**, 95 (1983).
23. C. E. Agarana, I. D. Kuntz, S. Birken, R. Azari, C. R. Cantor, *Nucleic Acids Res.* **14**, 1871 (1986).
24. J. Kraus, *Annu. Rev. Biochem.* **46**, 331 (1977).
25. T. C. Alber et al., *Cold Spring Harbor Symp. Quant. Biol.* **52**, 603 (1987).
26. The structure of a streptavidin:biotin complex has been determined independently by W. A. Hendrickson et al. (*Proc. Natl. Acad. Sci. U.S.A.*, in press).

4 November 1988; accepted 12 December 1988

BEST AVAILABLE COPY